RALLYBIO CORP (RLYB) Stock Price, Quote, News and Overview
NASDAQ:RLYB - Nasdaq - US75120L1008 - Common Stock - Currency: USD
RLYB Quote, Performance and Key Statistics
0.754
-0.02 (-2.09%)
The current stock price of RLYB is 0.754 USD. In the past month the price decreased by -17.63%. In the past year, price decreased by -55.65%.
RLYB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About RLYB
Company Profile
Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. The company is headquartered in New Haven, Connecticut and currently employs 25 full-time employees. The company went IPO on 2021-07-29. The company has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The company has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, RLYB331 and ENPP1 Program. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule with PK properties designed for the treatment of complement-mediated ophthalmic diseases. RLYB331 is for the treatment of severe anemia.
Company Info
RALLYBIO CORP
234 Church Street, Suite 1020
New Haven CONNECTICUT US
CEO: Martin W. Mackay
Employees: 25
Company Website: https://rallybio.com/
Investor Relations: https://investors.rallybio.com/
Phone: 12038593820
RALLYBIO CORP / RLYB FAQ
What is the stock price of RALLYBIO CORP today?
The current stock price of RLYB is 0.754 USD. The price decreased by -2.09% in the last trading session.
What is the ticker symbol for RALLYBIO CORP stock?
The exchange symbol of RALLYBIO CORP is RLYB and it is listed on the Nasdaq exchange.
On which exchange is RLYB stock listed?
RLYB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for RALLYBIO CORP stock?
11 analysts have analysed RLYB and the average price target is 8.41 USD. This implies a price increase of 1016.05% is expected in the next year compared to the current price of 0.754. Check the RALLYBIO CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is RALLYBIO CORP worth?
RALLYBIO CORP (RLYB) has a market capitalization of 31.28M USD. This makes RLYB a Nano Cap stock.
How many employees does RALLYBIO CORP have?
RALLYBIO CORP (RLYB) currently has 25 employees.
What are the support and resistance levels for RALLYBIO CORP (RLYB) stock?
RALLYBIO CORP (RLYB) has a resistance level at 0.79. Check the full technical report for a detailed analysis of RLYB support and resistance levels.
Should I buy RALLYBIO CORP (RLYB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RLYB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RLYB, evaluating the profitability, health, valuation and growth aspects
- RALLYBIO CORP (RLYB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- RALLYBIO CORP (RLYB) Sales and EPS estimates to see what analysts future expectations are.
- RALLYBIO CORP (RLYB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- RALLYBIO CORP (RLYB) Insider and Institutional Ownership to learn about the owners and their transactions.
- RALLYBIO CORP (RLYB) Stock Chart to make your own analysis
- RALLYBIO CORP (RLYB) Latest news and press-releases to stay up to date.
Does RALLYBIO CORP (RLYB) stock pay dividends?
RLYB does not pay a dividend.
What is the Price/Earnings (PE) ratio of RALLYBIO CORP (RLYB)?
RALLYBIO CORP (RLYB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.6).
What is the Short Interest ratio of RALLYBIO CORP (RLYB) stock?
The outstanding short interest for RALLYBIO CORP (RLYB) is 0.95% of its float. Check the ownership tab for more information on the RLYB short interest.
RLYB Technical Analysis
RLYB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RLYB. RLYB has a great financial health rating, but its profitability evaluates not so good.
RLYB Financial Highlights
Over the last trailing twelve months RLYB reported a non-GAAP Earnings per Share(EPS) of -1.6. The EPS increased by 11.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -84.77% | ||
| ROE | -94.57% | ||
| Debt/Equity | 0 |
RLYB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to RLYB. The Buy consensus is the average rating of analysts ratings from 11 analysts.